La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Opthea Crescita futura

Future criteri di controllo 5/6

Si prevede che Opthea aumenterà gli utili e i ricavi rispettivamente del 49.5% e 54.7% all'anno, mentre si prevede che l'EPS crescerà del 52.3% all'anno.

Informazioni chiave

57.9%

Tasso di crescita degli utili

60.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	14.6%
Tasso di crescita dei ricavi	53.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	30 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

ASX:OPT - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2027	177	36	-89	-29	5
6/30/2026	61	-79	-47	-9	8
6/30/2025	12	-150	-147	-139	7
6/30/2024	0	-220	-161	-161	N/A
3/31/2024	0	-191	-141	-141	N/A
12/31/2023	0	-162	-121	-121	N/A
9/30/2023	0	-152	-121	-121	N/A
6/30/2023	0	-143	-121	-121	N/A
3/31/2023	0	-137	-116	-116	N/A
12/31/2022	0	-132	-112	-112	N/A
9/30/2022	0	-113	-92	-92	N/A
6/30/2022	0	-93	-71	-71	N/A
3/31/2022	0	-75	-64	-64	N/A
12/31/2021	0	-57	-56	-56	N/A
9/30/2021	0	-51	-51	-51	N/A
6/30/2021	0	-45	-46	-46	N/A
3/31/2021	0	-39	-36	-36	N/A
12/31/2020	0	-31	-27	-27	N/A
9/30/2020	0	-21	-16	-16	N/A
6/30/2020	0	-11	-6	-6	N/A
3/31/2020	0	-10	-7	-7	N/A
12/31/2019	0	-12	-10	-10	N/A
9/30/2019	0	-13	-13	-13	N/A
6/30/2019	0	-15	-17	-17	N/A
3/31/2019	0	-13	-14	-14	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	0	-12	-13	-13	N/A
6/30/2018	0	-13	-15	-15	N/A
3/31/2018	0	-12	N/A	-13	N/A
12/31/2017	0	-12	N/A	-11	N/A
9/30/2017	0	-8	N/A	-8	N/A
6/30/2017	0	-5	N/A	-5	N/A
3/31/2017	0	-5	N/A	-4	N/A
12/31/2016	0	-5	N/A	-3	N/A
9/30/2016	0	-5	N/A	-3	N/A
6/30/2016	0	-5	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	0	-4	N/A	-4	N/A
3/31/2015	1	-4	N/A	-4	N/A
12/31/2014	1	-4	N/A	-4	N/A
9/30/2014	1	-4	N/A	-4	N/A
6/30/2014	1	-4	N/A	-4	N/A
3/31/2014	1	-3	N/A	-4	N/A
12/31/2013	1	-2	N/A	-4	N/A
9/30/2013	1	-3	N/A	-5	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che OPT diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Si prevede che OPT diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede OPT diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di OPT ( 54.7% all'anno) crescerà più rapidamente del mercato Australian ( 5.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di OPT ( 54.7% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di OPT è previsto essere elevato tra 3 anni

Opthea Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 10% to AU$0.79

Forecast to breakeven in 2027

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 10% to AU$0.79

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada